Table 1 Placebo and atypical antipsychotic response rates of selected comparator trials
Comparator | Study design | Dose (mg/day) | Definition of response | Placebo response rate (%) | Atypical response rate (%) | Reference(s) |
|---|---|---|---|---|---|---|
Paliperidone ER | 6 week study, patients with schizophrenia and acute exacerbation, olanzapine comparator | 3, 6, 9, and 12 | ≥ 30% decrease in PANSS from baseline to study endpoint | 27.4 | 50.8 | [21] [22] [23] |
Risperidone | 4 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation, aripiprazole comparator | 6 | ≥ 30% decrease in PANSS from baseline to study endpoint or CGI-I ≤ 2 | 23.3 | 40.0 | [35] |
Olanzapine | 6 week study, patients with schizophrenia and acute exacerbation, paliperidone ER comparator | 10 | ≥ 30% decrease in PANSS from baseline to study endpoint | 27.4 | 50.1 | [21] [22] [23] |
Quetiapine | 6 week study, inpatients with chronic or subchronic schizophrenia and acute exacerbation | 750 | ≥ 30% decrease in BPRS at any time during treatment | 35.0 | 49.0 | [41] |
Ziprasidone | 6 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation | 80 and 160 | ≥ 30% decrease in PANSS from baseline to study endpoint | 17.6 | 29.9 | [44] |
Aripiprazole | 4 week study, patients with schizophrenia or schizoaffective disorder and acute exacerbation, risperidone comparator | 20 and 30 | ≥ 30% decrease in PANSS from baseline to study endpoint or CGI-I ≤ 2 | 23.3 | 38.1 | [35] |